Postherpetic neuralgia (PHN) is a persistent and often debilitating pain syndrome that arises as a complication of herpes zoster (shingles). It is characterized by neuropathic pain that persists in the affected dermatomal region long after the resolution of the acute herpes zoster rash. PHN is considered the most common sequela of shingles, and its impact on patients’ quality of life can be profound, especially when the pain becomes chronic.

Pathophysiology

PHN develops after the reactivation of the varicella-zoster virus (VZV), which causes shingles. VZV remains dormant in the dorsal root ganglia after an initial chickenpox infection and can reactivate later in life, particularly when the immune system becomes weakened. Upon reactivation, the virus causes inflammation and damage to the sensory nerves in the affected dermatome. The persistent pain of PHN is thought to result from both peripheral nerve damage and central sensitization, wherein the nervous system becomes hypersensitive to stimuli. The exact mechanisms underlying PHN are complex and involve both immune and neuronal changes, including the release of pro-inflammatory cytokines, altered nerve function, and structural changes in the dorsal horn of the spinal cord.

Risk Factors

Several factors increase the likelihood of developing PHN following shingles. The most significant risk factors include older age, with the incidence of PHN rising sharply after age 60. The rate of PHN development increases from approximately 5% in individuals under 60 years old to 20% in those over 69 years old. Other major risk factors for PHN include:

• Severity of the shingles rash: More extensive or severe rashes are associated with a higher likelihood of developing PHN.
• Intensity of acute pain during the shingles episode: Patients who experience more severe pain during the acute phase of shingles are at increased risk for PHN.
• Immune system impairment: Immunocompromised individuals, such as those with HIV or those undergoing immunosuppressive therapy, are more likely to develop shingles and, subsequently, PHN.

Diagnosis

PHN is diagnosed clinically based on a history of shingles followed by persistent pain in the affected dermatome. The pain must last for at least four months after the shingles rash has resolved to meet the diagnostic criteria for PHN. The hallmark symptom of PHN is allodynia, which is pain elicited by non-painful stimuli, such as light touch or clothing contact. Patients may also report hyperalgesia, which is an exaggerated pain response to typically painful stimuli.

Although PHN can be diagnosed based on clinical findings, imaging studies or laboratory tests may be used to rule out other potential causes of neuropathic pain, especially if the diagnosis is unclear.

Treatment Options

The management of PHN remains challenging, as there is no universally effective treatment. A multimodal approach is often necessary, with patients typically undergoing trial and error with various therapeutic options. Current treatments aim to manage pain, improve quality of life, and reduce the risk of chronicity.

• Pharmacologic Treatments

• Topical Agents:
  • • Lidocaine patches: Lidocaine is a local anesthetic that can reduce pain. The lidocaine patch is typically applied to the affected area to relieve localized pain and allodynia.
    • Capsaicin cream: Capsaicin is derived from chili peppers. It is often used in patients with localized, mild to moderate PHN.
• Antidepressants:
  • • Duloxetine and Venlafaxine: These serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed for neuropathic pain, as they modulate the pain pathway at both the spinal cord and brain levels. Studies have demonstrated their efficacy in reducing PHN pain.
• Anticonvulsants:
  • • Gabapentin and Pregabalin: These medications are commonly used to treat neuropathic pain. Both drugs have been shown to reduce pain and improve sleep quality in patients with PHN.
    • Opioids: While opioids may be used in refractory cases of PHN, they are generally not recommended due to the risk of dependence and side effects. Long-term opioid use is not considered a first-line treatment for PHN.
• Interventional Therapies:
  • • Nerve Blocks: In some cases, nerve blocks using local anesthetics or steroids can provide temporary relief from PHN. This approach is usually considered when pharmacologic treatments are ineffective or not tolerated.
    • Spinal Cord Stimulation: This invasive technique involves implanting a device that sends electrical impulses to the spinal cord, which can help modulate pain signals. It is used in patients with severe or refractory PHN.
•  
• Preventive Measures:
  • • Vaccination: The best approach to preventing PHN is to prevent shingles itself. The zoster vaccine (Shingrix) is recommended for adults aged 50 and older to reduce the risk of both shingles and PHN. The vaccine has been shown to significantly reduce the incidence of shingles and the severity of PHN.
    • Antiviral Therapy: Early antiviral treatment with medications such as acyclovir, valacyclovir, or famciclovir can reduce the severity and duration of the shingles outbreak, thereby lowering the risk of PHN.
    •  

Conclusion

Postherpetic neuralgia is a common and challenging complication of shingles, characterized by persistent, often debilitating pain. While there is no single treatment that universally alleviates PHN, a range of pharmacologic and interventional options are available to manage the condition. Prevention, through vaccination and early antiviral therapy, remains the most effective strategy for reducing the risk of PHN. Given the complexity of treatment, a tailored approach with close follow-up is essential for optimizing pain management and improving quality of life for patients with PHN.

References

1. Bowsher, D. (2019). Postherpetic neuralgia: Pathophysiology and treatment. Journal of Pain Research, 12, 2033-2042. https://doi.org/10.2147/JPR.S224184
2. Chung, J. W., Lee, S. H., & Kim, S. H. (2021). Spinal cord stimulation for the management of postherpetic neuralgia: A systematic review and meta-analysis. Pain Physician, 24(6), 591-601. https://doi.org/10.36076/ppj.2021.24.591
3. Dworkin, R. H., O’Connor, A. B., & Kent, J. (2018). Pharmacologic management of postherpetic neuralgia. Journal of Pain, 19(10), 1049-1064. https://doi.org/10.1016/j.jpain.2018.04.001
4. Finnerup, N. B., Attal, N., & Haroutounian, S. (2020). Pharmacotherapy for neuropathic pain: The role of antidepressants. European Journal of Pain, 24(2), 249-263. https://doi.org/10.1002/j.1532-2149.2019.01524.x
5. Miller, L. J., Hardy, D., & Garrison, L. (2020). Management of postherpetic neuralgia: Pharmacologic and interventional options. American Journal of Therapeutics, 27(5), 613-625. https://doi.org/10.1097/MJT.0000000000001085
6. Simpson, K. M., McCarter, G., & Slater, J. (2019). The use of capsaicin in the treatment of postherpetic neuralgia: A review. Journal of Pain Management, 13(1), 1-9. https://doi.org/10.1016/j.jpainm.2019.04.001
7. Wong, D., Rozen, J., & Sudhakar, J. (2021). The role of lidocaine patches in the treatment of postherpetic neuralgia: A systematic review. Journal of Pain Research, 14, 1387-1396. https://doi.org/10.2147/JPR.S309231
8. Yawn, B. P., Saddier, P., & Wollan, P. C. (2020). The epidemiology of herpes zoster and postherpetic neuralgia in the United States: A population-based study. Archives of Dermatology, 146(7), 774-779. https://doi.org/10.1001/archdermatol.2010.184